MedDataX Logo

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT ID: NCT03906071

Last Updated: 2025-10-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

577 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-15

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

NCT05943795

Non-small Cell Lung Adenocarcinoma Squamous Cell Carcinoma of Lung
ACTIVE_NOT_RECRUITING PHASE3

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692

Advanced or Metastatic Non-Small Cell Lung Cancer
ACTIVE_NOT_RECRUITING PHASE3

Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.

NCT05791097

Non-small Cell Lung Cancer (NSCLC)
WITHDRAWN PHASE3

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

NCT00946712

Recurrent Large Cell Lung Carcinoma Recurrent Lung Adenocarcinoma Recurrent Squamous Cell Lung Carcinoma +3 more
TERMINATED PHASE3

S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00003158

Lung Cancer
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sitravatinib (MGCD516) is an orally-available, small molecule inhibitor of a closely related spectrum of receptor tyrosine kinases (RTKs) including MET, TAM (Tyro3, AXL, MERTK) family, VEGFR family, PDGFR family, KIT, FLT3, TRK family, RET, DDR2, and selected EPH family members. Nivolumab is a human IgG monoclonal antibody that binds to the PD-1 receptor and selectively blocks the interaction with its ligands PD-L1 and PD-L2, thereby releasing PD-1 pathway mediated inhibition of the immune response, including anti-tumor immune response. RTKs have been implicated in mediating an immunosuppressive tumor microenvironment, which has emerged as a potential resistance mechanism to checkpoint inhibitor therapy. Inhibition of these RTKs by sitravatinib may augment anti-tumor immune response and improve outcomes by overcoming resistance to checkpoint inhibitor therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Non-Squamous Non-Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nivolumab and Sitravatinib

Nivolumab will be administered by intravenous infusion over 30 minutes at 240 mg every 2 weeks or at 480 mg every 4 weeks. Sitravatinib capsules will be administered orally, once daily.

Group Type EXPERIMENTAL

Nivolumab

Intervention Type BIOLOGICAL

Nivolumab is an antibody directed at the programmed death receptor-1 (PD-1), blocking its interaction with PD-L1 and PD-L2.

Sitravatinib

Intervention Type DRUG

Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.

Docetaxel

Docetaxel will be administered by intravenous infusion at 75 mg/m2 over 1 hour every 3 weeks.

Group Type ACTIVE_COMPARATOR

Docetaxel

Intervention Type DRUG

Docetaxel is an anti-neoplastic agent that acts by disrupting the microtubular network in cells.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nivolumab

Nivolumab is an antibody directed at the programmed death receptor-1 (PD-1), blocking its interaction with PD-L1 and PD-L2.

Intervention Type BIOLOGICAL

Sitravatinib

Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.

Intervention Type DRUG

Docetaxel

Docetaxel is an anti-neoplastic agent that acts by disrupting the microtubular network in cells.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Opdivo MGCD516 Taxotere

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Non-Squamous Non-Small Cell Lung Cancer
* Receipt of at least one but not more than two prior treatment regimens in the advanced setting
* Prior treatment with PD-1/PD-L1 checkpoint inhibitor therapy and platinum-based chemotherapy in combination or in sequence (i.e., platinum-based chemotheraphy followed by checkpoint inhibitor therapy)
* Most recent treatment regimen must have included a checkpoint inhibitor therapy with radiographic disease progression on or after treatment
* Candidate to receive docetaxel as second or third line therapy

Exclusion Criteria

* Uncontrolled brain metastases
* Tumors that have tested positive for EGFR, ROS1, ALK mutations, or ALK fusions
* Unacceptable toxicity with prior checkpoint inhibitor therapy
* Receipt of systemic anti-cancer therapy post checkpoint inhibitor therapy, other than maintenance chemotherapy
* Impaired heart function
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bristol-Myers Squibb

INDUSTRY

Sponsor Role collaborator

Mirati Therapeutics Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Local Institution - 005-164

Birmingham, Alabama, United States

Site Status

Clearview Cancer Institute - Huntsville

Huntsville, Alabama, United States

Site Status

Palo Verde Cancer Specialists - Glendale

Glendale, Arizona, United States

Site Status

The Oncology Institute of Hope & Innovation - Tucson

Tucson, Arizona, United States

Site Status

Yuma Regional Medical Center

Yuma, Arizona, United States

Site Status

Local Institution - 005-174

Jonesboro, Arkansas, United States

Site Status

NEA Baptist Fowler Family Center for Cancer Care

Jonesboro, Arkansas, United States

Site Status

Highlands Oncology Group - Springdale

Springdale, Arkansas, United States

Site Status

Comprehensive Blood and Cancer Center - Bakersfield

Bakersfield, California, United States

Site Status

Local Institution - 005-118

Beverly Hills, California, United States

Site Status

Local Institution - 005-171

Fresno, California, United States

Site Status

Providence Medical Foundation - Virginia K. Crosson Cancer Center - Fullerton

Fullerton, California, United States

Site Status

Local Institution - 005-096

Long Beach, California, United States

Site Status

Cancer and Blood Specialty Clinic

Los Alamitos, California, United States

Site Status

Los Angeles Hematology Oncology Medical Group

Los Angeles, California, United States

Site Status

Local Institution - 005-185

Los Angeles, California, United States

Site Status

Local Institution - 005-072

Newport Beach, California, United States

Site Status

Local Institution - 005-109

Northridge, California, United States

Site Status

Local Institution - 005-177

Redlands, California, United States

Site Status

Local Institution - 005-112

Riverside, California, United States

Site Status

University of California San Francisco

San Francisco, California, United States

Site Status

Local Institution - 005-176

San Marcos, California, United States

Site Status

Local Institution - 005-192

Torrance, California, United States

Site Status

Local Institution - 005-090

West Covina, California, United States

Site Status

Local Institution - 005-105

Whittier, California, United States

Site Status

Local Institution - 005-097

Lafayette, Colorado, United States

Site Status

Eastern Connecticut Hematology and Oncology Associates

Norwich, Connecticut, United States

Site Status

Michael and Dianne Bienes Comprehensive Cancer Center

Fort Lauderdale, Florida, United States

Site Status

Local Institution - 005-120

Fort Myers, Florida, United States

Site Status

Memorial Regional Hospital

Hollywood, Florida, United States

Site Status

Watson Clinic Cancer and Research Center

Lakeland, Florida, United States

Site Status

Mount Sinai Health System

Miami Beach, Florida, United States

Site Status

Local Institution - 005-120E

Naples, Florida, United States

Site Status

Local Institution - 005-079

Ocala, Florida, United States

Site Status

Local Institution - 005-104

Orlando, Florida, United States

Site Status

SCRI - Florida Cancer Specialists - North Region Research Office

St. Petersburg, Florida, United States

Site Status

SCRI - Florida Cancer Specialists - Panhandle Research Office

Tallahassee, Florida, United States

Site Status

Local Institution - 005-154

West Palm Beach, Florida, United States

Site Status

University Cancer & Blood Center (UCBC) - Athens

Athens, Georgia, United States

Site Status

Local Institution - 005-146

Atlanta, Georgia, United States

Site Status

John B. Amos Cancer Center Research

Columbus, Georgia, United States

Site Status

Local Institution - 005-119

Marietta, Georgia, United States

Site Status

Straub Medical Center

Honolulu, Hawaii, United States

Site Status

Local Institution - 005-191

Coeur d'Alene, Idaho, United States

Site Status

Local Institution - 005-151

Chicago, Illinois, United States

Site Status

Local Institution - 005-110

Evanston, Illinois, United States

Site Status

Local Institution - 005-198

Niles, Illinois, United States

Site Status

Orchard Healthcare Research

Skokie, Illinois, United States

Site Status

Healthcare Research Network - Tinley Park

Tinley Park, Illinois, United States

Site Status

Fort Wayne Medical Oncology and Hematology - Fort Wayne South Office

Fort Wayne, Indiana, United States

Site Status

Local Institution - 005-122

Goshen, Indiana, United States

Site Status

Franciscan Health Cancer Center Indianapolis

Indianapolis, Indiana, United States

Site Status

Local Institution - 005-150

Lafayette, Indiana, United States

Site Status

Local Institution - 005-169

Westwood, Kansas, United States

Site Status

Local Institution - 005-098

Wichita, Kansas, United States

Site Status

Commonwealth Cancer Center - Frankfort

Danville, Kentucky, United States

Site Status

Local Institution - 005-153

Louisville, Kentucky, United States

Site Status

New England Cancer Specialists - Scarborough

Scarborough, Maine, United States

Site Status

Local Institution - 005-178

Rockville, Maryland, United States

Site Status

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

Local Institution - 005-127

Minneapolis, Minnesota, United States

Site Status

Local Institution - 005-159

Saint Louis Park, Minnesota, United States

Site Status

Jackson Oncology Associates - The Hederman Cancer Center

Jackson, Mississippi, United States

Site Status

Central Care Cancer Center - Bolivar

Bolivar, Missouri, United States

Site Status

Kansas City Care Health Center - Research Medical Campus

Kansas City, Missouri, United States

Site Status

Sisters of Charity of Leavenworth Health St. Marys

Billings, Montana, United States

Site Status

Saint Francis Cancer Treatment Center

Grand Island, Nebraska, United States

Site Status

Methodist Hospital - Omaha

Omaha, Nebraska, United States

Site Status

The Oncology Institute of Hope & Innovation - Henderson

Henderson, Nevada, United States

Site Status

Local Institution - 005-152

Henderson, Nevada, United States

Site Status

Local Institution - 005-142

Florham Park, New Jersey, United States

Site Status

Local Institution - 005-163

Little Silver, New Jersey, United States

Site Status

Cooperman Barnabas Medical Center

Livingston, New Jersey, United States

Site Status

Regional Cancer Care Associates - Sparta

Sparta, New Jersey, United States

Site Status

Local Institution - 005-123

Johnson City, New York, United States

Site Status

Local Institution - 005-182

Lake Success, New York, United States

Site Status

New York Cancer & Blood Specialists - Port Jefferson Medical Oncology

Port Jefferson Station, New York, United States

Site Status

Local Institution - 005-107

Stony Brook, New York, United States

Site Status

Local Institution - 005-196

Canton, Ohio, United States

Site Status

USOR - Oncology Hematology Care - Blue Ash

Cincinnati, Ohio, United States

Site Status

Local Institution - 005-181

Columbus, Ohio, United States

Site Status

Tricounty Hematology and Oncology - Massillon

Massillon, Ohio, United States

Site Status

Local Institution - 005-103

Toledo, Ohio, United States

Site Status

Local Institution - 005-088

Oklahoma City, Oklahoma, United States

Site Status

Providence Portland Medical Center

Portland, Oregon, United States

Site Status

Local Institution - 005-073

Portland, Oregon, United States

Site Status

USOR - Alliance Cancer Specialists - Horsham (Abington Hematology Oncology Associates)

Horsham, Pennsylvania, United States

Site Status

Local Institution - 005-186

Philadelphia, Pennsylvania, United States

Site Status

Local Institution - 005-137A

Dickson, Tennessee, United States

Site Status

Local Institution - 005-137B

Dickson, Tennessee, United States

Site Status

Local Institution - 005-137C

Dickson, Tennessee, United States

Site Status

Local Institution - 005-137D

Dickson, Tennessee, United States

Site Status

Local Institution - 005-137E

Dickson, Tennessee, United States

Site Status

Local Institution - 005-137F

Dickson, Tennessee, United States

Site Status

Local Institution - 005-137G

Dickson, Tennessee, United States

Site Status

Local Institution - 005-137H

Dickson, Tennessee, United States

Site Status

Local Institution - 005-137I

Dickson, Tennessee, United States

Site Status

Local Institution - 005-137J

Dickson, Tennessee, United States

Site Status

Local Institution - 005-137K

Dickson, Tennessee, United States

Site Status

Local Institution - 005-137L

Dickson, Tennessee, United States

Site Status

Local Institution - 005-137M

Hendersonville, Tennessee, United States

Site Status

Local Institution - 005-195

Memphis, Tennessee, United States

Site Status

Local Institution - 005-137

Nashville, Tennessee, United States

Site Status

Local Institution - 005-134

Austin, Texas, United States

Site Status

Local Institution - 005-075

Beaumont, Texas, United States

Site Status

Local Institution - 005-128

Dallas, Texas, United States

Site Status

Local Institution - 005-129

Dallas, Texas, United States

Site Status

Local Institution - 005-126

Dallas, Texas, United States

Site Status

USOR - Texas Oncology Northeast Texas - Denison

Denison, Texas, United States

Site Status

Local Institution - 005-124

Denton, Texas, United States

Site Status

The Center for Cancer & Blood Disorders - Fort Worth

Fort Worth, Texas, United States

Site Status

Oncology Consultants - Texas Medical Center

Houston, Texas, United States

Site Status

Local Institution - 005-076

Houston, Texas, United States

Site Status

Millennium Research and Clinical Development

Houston, Texas, United States

Site Status

USOR - US Oncology Investigational Products Center

Irving, Texas, United States

Site Status

Local Institution - 005-125

McKinney, Texas, United States

Site Status

Texas Oncology - San Antonio Medical Center

San Antonio, Texas, United States

Site Status

USOR - Texas Oncology - Sugar Land

Sugar Land, Texas, United States

Site Status

USOR - Texas Oncology Northeast Texas - Cancer and Research Institute - Tyler

Tyler, Texas, United States

Site Status

Local Institution - 005-144

Charlottesville, Virginia, United States

Site Status

Hematology Oncology Associates of Fredericksburg

Fredericksburg, Virginia, United States

Site Status

Virginia Cancer Institute - West End

Richmond, Virginia, United States

Site Status

Overlake Medical Center and Clinics

Bellevue, Washington, United States

Site Status

Local Institution - 005-082

Everett, Washington, United States

Site Status

Local Institution - 005-111

Seattle, Washington, United States

Site Status

Local Institution - 005-187

Spokane, Washington, United States

Site Status

Local Institution - 005-081

Tacoma, Washington, United States

Site Status

Northwest Medical Specialties - Tacoma

Tacoma, Washington, United States

Site Status

Local Institution - 005-136

Vancouver, Washington, United States

Site Status

ThedaCare Regional Cancer Center

Appleton, Wisconsin, United States

Site Status

Local Institution - 005-116

Madison, Wisconsin, United States

Site Status

Froedtert Hospital

Milwaukee, Wisconsin, United States

Site Status

Local Institution - 005-201

Brasschaat, , Belgium

Site Status

Local Institution - 005-200

Charleroi, , Belgium

Site Status

Local Institution - 005-206

Edegem, , Belgium

Site Status

Local Institution - 005-202

Ghent, , Belgium

Site Status

Local Institution - 005-207

Ghent, , Belgium

Site Status

Local Institution - 005-205

Roeselare, , Belgium

Site Status

Local Institution - 005-204

Ronse, , Belgium

Site Status

Centre Hospitalier Universitaire Universite Catholique de Louvain - Site Godinne

Yvoir, , Belgium

Site Status

Local Institution - 005-259

Calgary, Alberta, Canada

Site Status

Local Institution - 005-250

Moncton, New Brunswick, Canada

Site Status

Saint John Regional Hospital

Saint John, New Brunswick, Canada

Site Status

Local Institution - 005-252

Hamilton, Ontario, Canada

Site Status

Local Institution - 005-251

Toronto, Ontario, Canada

Site Status

Local Institution - 005-257

Windsor, Ontario, Canada

Site Status

Local Institution - 005-255

Montreal, Quebec, Canada

Site Status

Saskatoon Cancer Centre

Saskatoon, Saskatchewan, Canada

Site Status

Local Institution - 005-258

Québec, , Canada

Site Status

Local Institution - 005-307

Brest, , France

Site Status

Local Institution - 005-310

Bron, , France

Site Status

Local Institution - 005-311

Créteil, , France

Site Status

Local Institution - 005-303

Dijon, , France

Site Status

Local Institution - 005-309

Le Mans, , France

Site Status

Local Institution - 005-308

Limoges, , France

Site Status

Local Institution - 005-317

Lyon, , France

Site Status

Local Institution - 005-301

Marseille, , France

Site Status

Local Institution - 005-312

Marseille, , France

Site Status

Local Institution - 005-313

Montpellier, , France

Site Status

Local Institution - 005-306

Mulhouse, , France

Site Status

Local Institution - 005-302

Paris, , France

Site Status

Local Institution - 005-314

Rouen, , France

Site Status

Local Institution - 005-316

Saint-Herblain, , France

Site Status

Local Institution - 005-305

Strasbourg, , France

Site Status

Local Institution - 005-304

Villejuif, , France

Site Status

Local Institution - 005-400

Bad Berka, , Germany

Site Status

Local Institution - 005-418

Berlin, , Germany

Site Status

Local Institution - 005-401

Bonn, , Germany

Site Status

Local Institution - 005-412

Cologne, , Germany

Site Status

Local Institution - 005-419

Essen, , Germany

Site Status

Local Institution - 005-406

Esslingen am Neckar, , Germany

Site Status

Local Institution - 005-403

Gauting, , Germany

Site Status

Local Institution - 005-417

Grohansdorf, , Germany

Site Status

Local Institution - 005-408

Halle, , Germany

Site Status

Local Institution - 005-411

Immenstadt im Allgäu, , Germany

Site Status

Local Institution - 005-416

Kassel, , Germany

Site Status

Local Institution - 005-410

Löwenstein, , Germany

Site Status

Local Institution - 005-405

Lübeck, , Germany

Site Status

Local Institution - 005-414

Mainz, , Germany

Site Status

Local Institution - 005-413

München, , Germany

Site Status

Local Institution - 005-402

München, , Germany

Site Status

Local Institution - 005-454

Budapest, , Hungary

Site Status

Local Institution - 005-457

Budapest, , Hungary

Site Status

Local Institution - 005-455

Budapest, , Hungary

Site Status

Local Institution - 005-453

Farkasgyepű, , Hungary

Site Status

Local Institution - 005-452

Győr, , Hungary

Site Status

Local Institution - 005-451

Szombathely, , Hungary

Site Status

Local Institution - 005-450

Tatabánya, , Hungary

Site Status

Local Institution - 005-456

Törökbálint, , Hungary

Site Status

Local Institution - 005-500

Afula, , Israel

Site Status

Local Institution - 005-501

Beer Yaakov, , Israel

Site Status

Local Institution - 005-504

Beersheba, , Israel

Site Status

Local Institution - 005-502

Holon, , Israel

Site Status

Local Institution - 005-507

Jerusalem, , Israel

Site Status

Local Institution - 005-506

Ramat Gan, , Israel

Site Status

Local Institution - 005-505

Zsfat, , Israel

Site Status

Local Institution - 005-612

Alessandria, , Italy

Site Status

Local Institution - 005-602

Bari, , Italy

Site Status

Local Institution - 005-603

Catania, , Italy

Site Status

Local Institution - 005-611

Cremona, , Italy

Site Status

Local Institution - 005-608

Lecce, , Italy

Site Status

Local Institution - 005-610

Meldola, , Italy

Site Status

Local Institution - 005-606

Milan, , Italy

Site Status

Local Institution - 005-605

Monza, , Italy

Site Status

Local Institution - 005-604

Napoli, , Italy

Site Status

Local Institution - 005-600

Parma, , Italy

Site Status

Local Institution - 005-607

Piacenza, , Italy

Site Status

Local Institution - 005-609

Pisa, , Italy

Site Status

Local Institution - 005-614

Roma, , Italy

Site Status

Ospedale di Circolo e Fondazione Macchi

Varese, , Italy

Site Status

Local Institution - 005-700

's-Hertogenbosch, , Netherlands

Site Status

Local Institution - 005-703

Amsterdam, , Netherlands

Site Status

Local Institution - 005-711

Amsterdam, , Netherlands

Site Status

Local Institution - 005-707

Breda, , Netherlands

Site Status

Local Institution - 005-713

Dordrecht, , Netherlands

Site Status

Local Institution - 005-702

Groningen, , Netherlands

Site Status

Local Institution - 005-712

Maastricht, , Netherlands

Site Status

Local Institution - 005-714

Nijmegen, , Netherlands

Site Status

Local Institution - 005-710

Rotterdam, , Netherlands

Site Status

Local Institution - 005-705

Rotterdam, , Netherlands

Site Status

Local Institution - 005-709

The Hague, , Netherlands

Site Status

Local Institution - 005-701

Utrecht, , Netherlands

Site Status

Local Institution - 005-708

Utrecht, , Netherlands

Site Status

Local Institution - 005-706

Zwolle, , Netherlands

Site Status

Local Institution - 005-807

A Coruña, , Spain

Site Status

Local Institution - 005-800

Badalona, , Spain

Site Status

Local Institution - 005-822

Barcelona, , Spain

Site Status

Local Institution - 005-811

Barcelona, , Spain

Site Status

Local Institution - 005-810

Barcelona, , Spain

Site Status

Local Institution - 005-805

Jaén, , Spain

Site Status

Local Institution - 005-816

Las Palmas de Gran Canaria, , Spain

Site Status

Local Institution - 005-817

León, , Spain

Site Status

Local Institution - 005-812

Lugo, , Spain

Site Status

Hospital Universitario La Princesa

Madrid, , Spain

Site Status

Local Institution - 005-808

Madrid, , Spain

Site Status

Local Institution - 005-819

Madrid, , Spain

Site Status

Local Institution - 005-821

Madrid, , Spain

Site Status

Local Institution - 005-813

Madrid, , Spain

Site Status

Local Institution - 005-815

Madrid, , Spain

Site Status

Local Institution - 005-809

Madrid, , Spain

Site Status

Hospital Universitario La Paz

Madrid, , Spain

Site Status

Local Institution - 005-806

Majadahonda, , Spain

Site Status

Local Institution - 005-801

Málaga, , Spain

Site Status

Local Institution - 005-803

Oviedo, , Spain

Site Status

Local Institution - 005-823

Santiago de Compostela, , Spain

Site Status

IVO - Fundacion Instituto Valenciano de Oncologia

Valencia, , Spain

Site Status

Local Institution - 005-804

Valencia, , Spain

Site Status

Local Institution - 005-818

Vigo, , Spain

Site Status

Inselspital Universitatsspital Bern

Bern, , Switzerland

Site Status

Hopitaux Universitaires de Geneve

Geneva, , Switzerland

Site Status

Centre Hospitalier Universitaire Vaudois Lausanne

Lausanne, , Switzerland

Site Status

Kantonsspital Winterthur

Winterthur, , Switzerland

Site Status

Velindre University NHS Trust

Cardiff, , United Kingdom

Site Status

Local Institution - 005-904

Cornwall, , United Kingdom

Site Status

University Hospitals of Leicester NHS Trust

Leicester, , United Kingdom

Site Status

Local Institution - 005-908

London, , United Kingdom

Site Status

Local Institution - 005-900

London, , United Kingdom

Site Status

The Royal Marsden NHS Foundation Trust

London, , United Kingdom

Site Status

The Christie NHS Foundation Trust

Manchester, , United Kingdom

Site Status

Local Institution - 005-903

Middlesex, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium Canada France Germany Hungary Israel Italy Netherlands Spain Switzerland United Kingdom

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

BMS Clinical Trial Information

https://www.BMSClinicalTrials.com

BMS Clinical Trial Patient Recruiting

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CA248-0001

Identifier Type: OTHER

Identifier Source: secondary_id

516-005

Identifier Type: OTHER

Identifier Source: secondary_id

CA248-0001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734 ACTIVE_NOT_RECRUITING PHASE3
Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer
NCT02613507 COMPLETED PHASE3
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
NCT03406715 TERMINATED PHASE2
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
NCT03041181 TERMINATED PHASE2
NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
NCT02434081 COMPLETED PHASE2
2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)
NCT00835471 COMPLETED PHASE2
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
NCT03215810 COMPLETED PHASE1
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
NCT04475939 ACTIVE_NOT_RECRUITING PHASE3
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT02574078 COMPLETED PHASE1/PHASE2
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00040794 COMPLETED PHASE2
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT04025879 ACTIVE_NOT_RECRUITING PHASE3
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
NCT02954991 TERMINATED PHASE2
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
NCT04026412 COMPLETED PHASE3
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
NCT02106546 COMPLETED PHASE3
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
NCT03043599 COMPLETED PHASE1/PHASE2
Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer
NCT03091491 TERMINATED PHASE2
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
NCT02511184 TERMINATED PHASE1
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
NCT03215706 COMPLETED PHASE3
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
NCT03583086 COMPLETED PHASE1/PHASE2
First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial
NCT05648071 UNKNOWN PHASE3
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
NCT02264990 COMPLETED PHASE3
Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer
NCT00819728 COMPLETED PHASE2
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
NCT07082179 NOT_YET_RECRUITING PHASE2
An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT03001882 COMPLETED PHASE2
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT04623775 ACTIVE_NOT_RECRUITING PHASE2